AbbVie announced a definitive agreement to acquire Capstan Therapeutics for up to USD 2.1 billion, gaining rights to its lead candidate CPTX2309, a targeted lipid nanoparticle (tLNP) delivering mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8+ T-cells in vivo. Currently in Phase I trials for B cell-mediated autoimmune diseases, CPTX2309 eliminates the need for lymphodepletion or ex vivo cell manufacturing.
The acquisition includes Capstan's proprietary tLNP platform, designed to enable in vivo cell engineering via RNA payload delivery. AbbVie aims to leverage this technology to develop potential immune-resetting therapies for autoimmune conditions.
The transaction, subject to regulatory approvals, is expected to close following US regulatory clearance. Centerview Partners advised Capstan on the deal.
1751594149142.png)